ClinicalTrials.gg
TerminatedNCT04735575Updated May 28, 2025

A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

A Phase 1/2 interventional study of EMB-06 in Relapsed or Refractory Multiple Myeloma, sponsored by Shanghai EpimAb Biotherapeutics Co., Ltd.. Terminated at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-28.

Primary conditionMultiple MyelomaRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Myeloma
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Multiple Myeloma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Shanghai EpimAb Biotherapeutics Co., Ltd. · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Company's resource optimization and product's development change

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 448 studies in Multiple Myeloma with a site in China — 238 open to participants now, 275 under way, 47 of them phase 3. Multiple Myeloma · China.

Enrollment
201st of 406
40 · median 40
Started
2021
with 42 others
Phase 1/2
65 of 448
43 open now
Registered
135th of 448
by date

Among the 448 studies in Multiple Myeloma with a site in China, this one is the 201st largest by enrollment of the 406 interventional ones that give a count, is one of 43 that started in 2021, is one of 65 in phase 1/2, and was the 135th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

238 of the 448 studies in Multiple Myeloma with a site in China are open now. Recruiting first, the newest first:

233 more — sign in →

All 238 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Multiple Myeloma with a site in China, or all of them as a file.
02

Study summary

The primary purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for EMB-06 and to characterize the safety and tolerability of EMB-06 at the RP2Ds. Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma activity of EMB-06 will also be assessed.

Read the detailed description

This is a Phase I/II, multi-center, open label, multiple-dose, first in human study, designed to assess safety and tolerability, and to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) for EMB-06 in patients with relapsed or refractory multiple myeloma. Pharmacokinetics, pharmacodynamics, immunogenicity, and response will also be assessed.

03

Conditions studied

  • Relapsed or Refractory Multiple Myeloma

Browse trials for

Keywords

  • Phase I/II
  • Bispecific antibody
  • BCMA
  • CD3
  • EMB-06
  • Immuno-oncology
  • Dose escalation
  • Cohort expansion
  • Relapsed or Refractory Multiple Myeloma
  • Hematological malignancy
04

In context

Multiple Myeloma Reclassified

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

This study's enrollment of 40 is close to the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

Shanghai EpimAb Biotherapeutics Co., Ltd. is the lead sponsor of 10 studies on the registry; 8 are open to participants now.

Compared within Multiple Myeloma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to understand and willing to sign the form (ICF)
  • Patients who have been diagnosed with multiple myeloma according to IMWG diagnostic criteria 2014 and have multiple myeloma with at least one .
  • The patient must have received at least two lines (for patients in the US, at least three lines which should include anti-CD38 antibody) of prior antimyeloma therapies, and must have received treatment with proteasome inhibitors, immunomodulatory agents, and if accessible, an anti-CD38 targeting monoclonal antibody.
  • performance status 0 or 1 for phase I, and ≤2 for phase II.
  • Adequate organ function and reasonable laboratory test results to participate in the trial.
  • Highly effective

Exclusion criteria

Exclusion Criteria:

  • is less than 3 months.
  • Patient participated in any other clinical study within 1 month prior to enrollment in this clinical study.
  • Patients with ongoing AE.
  • Previously treated with any BCMA-targeted therapy.(Exception: in Phase 2 portion, up to 10 patients who have received prior anti-BCMA ADC or BCMA targeted CAR-T can be enrolled)
  • History of stem cell transplantation.
  • Previously treated with the following anti-tumor therapy (prior to first dosing of EMB-06)

    1. Treated with monoclonal antibody for multiple myeloma within 28 days
    2. Treated with proteasome inhibitors within 14 days
    3. Treated with immunomodulatory agents within 14 days
    4. Treated with cytotoxic therapy within 14 days
    5. Received drug within 28 days or at least 5 half-lives, whichever is shorter (if a, b, c, d not applicable)
    6. Received radiotherapy within 21 days. Except that the radiation portal covered ≤ 5% of the bone marrow reserve, the patient will be eligible to participate in the study regardless of the end date of radiation therapy
    7. Plasmapheresis within 7 days
  • Patient received autologous stem cell transplantation within 12 weeks prior to the start of study treatment.
  • Active or historically multiple myeloma related central nervous system involvement.
  • Patients requiring high dose of systemic treatment with .
  • Patients with active infections, including COVID-19, hepatitis, etc..
  • History of severe allergic reactions
  • Patients with severe or uncontrolled cardiovascular disorder requiring treatment
  • Pre-existing other serious medical conditions
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    EMB-06

    In Phase I part: participants enrolled at different time will receive EMB-06 by IV infusion at different ascending dose levels. In Phase II part: participants will receive EMB-06 by IV infusion at previously defined RP2D.

    Biological: EMB-06

Interventions

  • BiologicalEMB-06

    EMB-06 is a FIT-Ig® bispecific antibody against BCMA and CD3.

07

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events

    Incidence and severity of AE.

    Time frame: Screening up to follow-up (30 days after the last dose)

  2. Incidence of serious adverse events (SAE)

    Incidence of SAE

    Time frame: Screening up to follow-up (30 days after the last dose)

  3. Incidence of dose interruptions.

    Incidence of dose interruptions of EMB-06 during treatment as a measure of tolerability.

    Time frame: Screening up to follow-up (30 days after the last dose)

  4. Dose intensity

    Actual amount of drug taken by patients divided by the planned amount.

    Time frame: Screening up to follow-up (30 days after the last dose)

  5. The incidence of DLTs during treatment.

    The Dose Limiting Toxicities (DLTs) are based on drug related adverse events and are specifically defined in study protocol.

    Time frame: First infusion to the end of Cycle 1 (each cycle is 28 days)

  6. Overall Response Rate (ORR)

    Measured by IMWG criteria, only applicable in Phase II part

    Time frame: From the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, expected average 6 months

Secondary outcomes

  1. Area under the serum concentration-time curve (AUC) of EMB-06.

    Blood samples for serum PK analysis will be obtained (AUC).

    Time frame: Through treatment until EOT visit, expected average 6 months

  2. Maximum serum concentration (Cmax) of EMB-06.

    Blood samples for serum PK analysis will be obtained (Cmax).

    Time frame: Through treatment until EOT visit, expected average 6 months

  3. Trough concentration (Ctrough) of EMB-06.

    Blood samples for serum PK analysis will be obtained (Ctrough).

    Time frame: Through treatment until EOT visit, expected average 6 months

  4. Average concentration over a dosing interval (Css, avg) of EMB-06.

    Blood samples for serum PK analysis will be obtained (Css, avg).

    Time frame: Through treatment until EOT visit, expected average 6 months

  5. Terminal half-life (T1/2) of EMB-06.

    Blood samples for serum PK analysis will be obtained (T1/2).

    Time frame: Through treatment until EOT visit, expected average 6 months

  6. Systemic clearance (CL) of EMB-06.

    Blood samples for serum PK analysis will be obtained (CL).

    Time frame: Through treatment until EOT visit, expected average 6 months

  7. Steady state volume of distribution (Vss) of EMB-06.

    Blood samples for serum PK analysis will be obtained (Vss).

    Time frame: Through treatment until EOT visit, expected average 6 months

  8. Progression free survival (PFS) of EMB-06 as assessed by IMWG criteria.

    Preliminary anti-multiple myeloma activity of EMB-06 will be obtained (PFS).

    Time frame: From the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, expected average 6 months

  9. Duration of response of EMB-06 as assessed by IMWG criteria

    Preliminary anti-multiple myeloma activity of EMB-06 will be obtained (DOR).

    Time frame: From the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, expected average 6 months

  10. Incidence and titer of anti-drug antibodies stimulated by EMB-06.

    Antibodies to EMB-06 will be assessed to evaluate potential immunogenicity.

    Time frame: Up to End of Treatment Follow Up Period (30 days after the last dose)

08

Study locations

10 sites
  • Sunshine Coast Haematology and Oncology Clinic (SCHOC)
    Buderim, Queensland 4556, Australia
  • Epworth Healthcare
    Richmond, Victoria 3121, Australia
  • One Clinical Research (OCR)
    Nedlands, Western Australia 6009, Australia
  • Beijing Jishuitan Hospital
    Beijing, Beijing 100035, China
  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai 200020, China
  • Peking University, Third Hospital
    Beijing, China
  • Guangdong Provincial People's Hospital
    Guangzhou, China
  • The First Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, China
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, China
  • Henan Cancer Hospital
    Zhengzhou, China
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Aug 2024, 39 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2021
First posted
Feb 3, 2021
StartActual
May 20, 2021
Primary completionActual
Aug 20, 2024
CompletionActual
Aug 20, 2024
Last update
May 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04735575
Lead sponsor
Shanghai EpimAb Biotherapeutics Co., Ltd.
Responsible party
Sponsor
First posted
Feb 3, 2021
Start date
May 20, 2021
Primary completion
Aug 20, 2024
Completion
Aug 20, 2024
Last update
May 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cizutamig

Start the discussion